Carisma Therapeutics (NASDAQ:CARM) Given New $1.00 Price Target at D. Boral Capital
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price objective cut by equities researchers at D. Boral Capital from $12.00 to $1.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. D. Boral Capital’s target price would indicate a potential upside of 350.05% from the stock’s […]
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price objective cut by equities researchers at D. Boral Capital from $12.00 to $1.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. D. Boral Capital’s target price would indicate a potential upside of 350.05% from the stock’s […]
